Loading...

OptimizeRx

Nasdaq:OPRX
Snowflake Description

High growth potential with excellent balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
OPRX
Nasdaq
$189M
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

OptimizeRx Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers. The last earnings update was 8 days ago. More info.


Add to Portfolio Compare Print
  • OptimizeRx has significant price volatility in the past 3 months.
OPRX Share Price and Events
7 Day Returns
17.6%
NasdaqCM:OPRX
-3.2%
US Healthcare Services
-3.9%
US Market
1 Year Returns
92.6%
NasdaqCM:OPRX
25.9%
US Healthcare Services
1.4%
US Market
OPRX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
OptimizeRx (OPRX) 17.6% 30.5% 21.8% 92.6% 386% 205.9%
US Healthcare Services -3.2% 3.5% 6.4% 25.9% 71.2% 60.3%
US Market -3.9% -3.6% 1.8% 1.4% 35.8% 40.8%
1 Year Return vs Industry and Market
  • OPRX outperformed the Healthcare Services industry which returned 25.9% over the past year.
  • OPRX outperformed the Market in United States of America which returned 1.4% over the past year.
Price Volatility
OPRX
Industry
5yr Volatility vs Market
Related Companies

OPRX Value

 Is OptimizeRx undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of OptimizeRx to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for OptimizeRx.

NasdaqCM:OPRX Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 4 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 9.6%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqCM:OPRX
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Healthcare Services Unlevered Beta Simply Wall St/ S&P Global 1.23
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.232 (1 + (1- 21%) (0.34%))
1.158
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.16
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.158 * 5.96%)
9.63%

Discounted Cash Flow Calculation for NasdaqCM:OPRX using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for OptimizeRx is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqCM:OPRX DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 9.63%)
2019 1.79 Analyst x1 1.63
2020 8.82 Analyst x2 7.34
2021 14.92 Est @ 69.23% 11.32
2022 22.27 Est @ 49.28% 15.42
2023 30.14 Est @ 35.32% 19.03
2024 37.84 Est @ 25.54% 21.79
2025 44.91 Est @ 18.7% 23.59
2026 51.16 Est @ 13.91% 24.52
2027 56.55 Est @ 10.55% 24.72
2028 61.20 Est @ 8.21% 24.40
Present value of next 10 years cash flows $173.77
NasdaqCM:OPRX DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $61.20 × (1 + 2.73%) ÷ (9.63% – 2.73%)
$911.04
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $911.04 ÷ (1 + 9.63%)10
$363.26
NasdaqCM:OPRX Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $173.77 + $363.26
$537.03
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $537.03 / 12.10
$44.4
NasdaqCM:OPRX Discount to Share Price
Calculation Result
Value per share (USD) From above. $44.40
Current discount Discount to share price of $15.60
= -1 x ($15.60 - $44.40) / $44.40
64.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price OptimizeRx is available for.
Intrinsic value
>50%
Share price is $15.6 vs Future cash flow value of $44.4
Current Discount Checks
For OptimizeRx to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • OptimizeRx's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • OptimizeRx's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for OptimizeRx's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are OptimizeRx's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:OPRX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $0.04
NasdaqCM:OPRX Share Price ** NasdaqCM (2019-05-15) in USD $15.6
United States of America Healthcare Services Industry PE Ratio Median Figure of 13 Publicly-Listed Healthcare Services Companies 56.02x
United States of America Market PE Ratio Median Figure of 3,087 Publicly-Listed Companies 17.79x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of OptimizeRx.

NasdaqCM:OPRX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:OPRX Share Price ÷ EPS (both in USD)

= 15.6 ÷ 0.04

421.56x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • OptimizeRx is overvalued based on earnings compared to the US Healthcare Services industry average.
  • OptimizeRx is overvalued based on earnings compared to the United States of America market.
Price based on expected Growth
Does OptimizeRx's expected growth come at a high price?
Raw Data
NasdaqCM:OPRX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 421.56x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
98.1%per year
United States of America Healthcare Services Industry PEG Ratio Median Figure of 12 Publicly-Listed Healthcare Services Companies 2.31x
United States of America Market PEG Ratio Median Figure of 2,113 Publicly-Listed Companies 1.52x

*Line of best fit is calculated by linear regression .

NasdaqCM:OPRX PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 421.56x ÷ 98.1%

4.3x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • OptimizeRx is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on OptimizeRx's assets?
Raw Data
NasdaqCM:OPRX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $1.58
NasdaqCM:OPRX Share Price * NasdaqCM (2019-05-15) in USD $15.6
United States of America Healthcare Services Industry PB Ratio Median Figure of 34 Publicly-Listed Healthcare Services Companies 4.2x
United States of America Market PB Ratio Median Figure of 5,195 Publicly-Listed Companies 1.83x
NasdaqCM:OPRX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:OPRX Share Price ÷ Book Value per Share (both in USD)

= 15.6 ÷ 1.58

9.85x

* Primary Listing of OptimizeRx.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • OptimizeRx is overvalued based on assets compared to the US Healthcare Services industry average.
X
Value checks
We assess OptimizeRx's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare Services industry average (and greater than 0)? (1 check)
  5. OptimizeRx has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

OPRX Future Performance

 How is OptimizeRx expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
98.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is OptimizeRx expected to grow at an attractive rate?
  • OptimizeRx's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • OptimizeRx's earnings growth is expected to exceed the United States of America market average.
  • OptimizeRx's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:OPRX Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqCM:OPRX Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 98.1%
NasdaqCM:OPRX Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 27.2%
United States of America Healthcare Services Industry Earnings Growth Rate Market Cap Weighted Average 25.4%
United States of America Healthcare Services Industry Revenue Growth Rate Market Cap Weighted Average 11.6%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:OPRX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:OPRX Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 36 6 4 3
2019-12-31 28 4 2 4
NasdaqCM:OPRX Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 22 2 0
2018-12-31 21 1 0
2018-09-30 19 0 0
2018-06-30 16 -2 -1
2018-03-31 14 -2 -1
2017-12-31 12 -1 -2
2017-09-30 10 -2 -2
2017-06-30 9 -1 -2
2017-03-31 8 0 -2
2016-12-31 8 0 -2
2016-09-30 7 0 -2
2016-06-30 8 0 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • OptimizeRx's earnings are expected to grow significantly at over 20% yearly.
  • OptimizeRx's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:OPRX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from OptimizeRx Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:OPRX Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31 0.32 0.47 0.16 2.00
2019-12-31 0.15 0.23 0.10 3.00
NasdaqCM:OPRX Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 0.04
2018-12-31 0.02
2018-09-30 0.01
2018-06-30 -0.08
2018-03-31 -0.14
2017-12-31 -0.21
2017-09-30 -0.22
2017-06-30 -0.18
2017-03-31 -0.21
2016-12-31 -0.16
2016-09-30 -0.16
2016-06-30 -0.14

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if OptimizeRx will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess OptimizeRx's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
OptimizeRx has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

OPRX Past Performance

  How has OptimizeRx performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare OptimizeRx's growth in the last year to its industry (Healthcare Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • OptimizeRx's year on year earnings growth rate has been positive over the past 5 years.
  • OptimizeRx has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • OptimizeRx has become profitable in the last year making it difficult to compare the US Healthcare Services industry average.
Earnings and Revenue History
OptimizeRx's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from OptimizeRx Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:OPRX Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 22.30 0.42 12.17
2018-12-31 21.21 0.23 10.97
2018-09-30 18.63 0.10 10.36
2018-06-30 16.32 -0.77 9.46
2018-03-31 14.09 -1.41 8.42
2017-12-31 12.13 -2.10 7.39
2017-09-30 10.41 -2.22 6.70
2017-06-30 9.10 -1.84 6.08
2017-03-31 8.14 -2.07 6.05
2016-12-31 7.75 -1.54 5.64
2016-09-30 7.48 -1.60 1.96
2016-06-30 7.70 -1.27 1.49
2016-03-31 7.49 -0.84 1.04
2015-12-31 7.22 -0.60 0.63
2015-09-30 7.17 0.05 0.77
2015-06-30 6.98 -0.33 1.07
2015-03-31 6.70 -0.37 1.00
2014-12-31 6.50 -1.03 1.26
2014-09-30 6.07 -1.13 1.41
2014-06-30 5.62 -0.98 1.23
2014-03-31 5.30 -0.80 0.88
2013-12-31 4.68 -0.27 0.57
2013-09-30 3.84 -0.36 3.71
2013-06-30 2.92 -0.33 3.01
2013-03-31 2.33 -0.38 2.68
2012-12-31 1.99 -0.45 2.14
2012-09-30 1.62 -0.58 0.99
2012-06-30 1.36 -1.56 1.15

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • OptimizeRx has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • OptimizeRx used its assets less efficiently than the US Healthcare Services industry average last year based on Return on Assets.
  • OptimizeRx has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess OptimizeRx's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
OptimizeRx has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

OPRX Health

 How is OptimizeRx's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up OptimizeRx's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • OptimizeRx is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • OptimizeRx's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of OptimizeRx's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 23.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from OptimizeRx Company Filings, last reported 1 month ago.

NasdaqCM:OPRX Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 19.44 0.65 10.13
2018-12-31 18.46 0.00 8.91
2018-09-30 17.20 0.00 13.52
2018-06-30 15.80 0.00 12.00
2018-03-31 6.83 0.00 4.30
2017-12-31 6.22 0.00 5.12
2017-09-30 6.05 0.00 5.01
2017-06-30 6.47 0.00 5.84
2017-03-31 7.06 0.00 6.72
2016-12-31 7.81 0.00 7.03
2016-09-30 8.04 0.00 7.57
2016-06-30 8.16 0.00 7.57
2016-03-31 8.55 0.00 7.55
2015-12-31 8.94 0.00 8.21
2015-09-30 9.24 0.00 8.17
2015-06-30 4.70 0.00 3.65
2015-03-31 4.58 0.00 3.51
2014-12-31 4.61 0.00 3.45
2014-09-30 4.85 0.00 3.26
2014-06-30 4.78 0.00 3.55
2014-03-31 4.60 0.00 4.03
2013-12-31 1.67 0.00 1.12
2013-09-30 2.07 0.00 0.49
2013-06-30 1.78 0.00 0.35
2013-03-31 1.39 0.00 0.26
2012-12-31 1.40 0.00 0.28
2012-09-30 1.33 0.00 0.28
2012-06-30 1.39 0.00 0.53
  • OptimizeRx's level of debt (3.3%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 3.3% today).
  • Debt is well covered by operating cash flow (381.3%, greater than 20% of total debt).
  • OptimizeRx earns more interest than it pays, coverage of interest payments is not a concern.
X
Financial health checks
We assess OptimizeRx's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. OptimizeRx has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

OPRX Dividends

 What is OptimizeRx's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from OptimizeRx dividends.
If you bought $2,000 of OptimizeRx shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate OptimizeRx's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate OptimizeRx's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:OPRX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Global Healthcare Services Industry Average Dividend Yield Market Cap Weighted Average of 14 Stocks 1.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1997 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqCM:OPRX Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as OptimizeRx has not reported any payouts.
  • Unable to verify if OptimizeRx's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of OptimizeRx's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as OptimizeRx has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess OptimizeRx's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can OptimizeRx afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. OptimizeRx has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

OPRX Management

 What is the CEO of OptimizeRx's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Will Febbo
COMPENSATION $923,138
AGE 49
TENURE AS CEO 3.3 years
CEO Bio

Mr. William J. Febbo, also known as Will, has been the Chief Executive Officer and Director of OptimizeRx Corp since February 22, 2016. Mr. Febbo is a Founder of Plexuus, an early stage payment processing platform for medical professionals with Sunshine Act-related activities. Mr. Febbo has more than 18 years of experience in building and managing health services and financial businesses. Mr. Febbo served as Chairman and Founder of Plexus, LLC, a payment processing business for medical professionals. He was a Director of the Merriman Holdings, Inc. (“Merriman”) from April 2007 to February 2016. When Febbo sold it in 2007 to Merriman Capital, he held dual roles as COO of the bank and CEO of Digital Capital Network which he launched pioneering digital compliance & transparency in the financial industry. He joined MIT linQ as a faculty member. Hehas participated in two of these programs, IMPACT and Idea2 global. He advises several companies in the US, Spain and South America and has a passion for reviving existing businesses with disruptive technology. Prior to Merriman, He founded and ran MedPanel, LLC in 1999. He has been Treasurer of the Board of the United Nations of Greater Boston since November 2004. He holds a Bachelor of Arts in International Studies from Dickinson College, in Pennsylvania.

CEO Compensation
  • Will's compensation has increased in line with OptimizeRx recently becoming profitable.
  • Will's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the OptimizeRx management team in years:

2.8
Average Tenure
53
Average Age
  • The tenure for the OptimizeRx management team is about average.
Management Team

Will Febbo

TITLE
CEO & Director
COMPENSATION
$923K
AGE
49
TENURE
3.3 yrs

Miriam Paramore

TITLE
President
COMPENSATION
$445K
AGE
55
TENURE
1.8 yrs

Doug Baker

TITLE
Chief Financial Officer
COMPENSATION
$426K
AGE
61
TENURE
5 yrs

Terry Hamilton

TITLE
Senior Vice President of Sales
COMPENSATION
$512K
AGE
53
TENURE
3.3 yrs

Steve Silvestro

TITLE
Chief Commercial Officer
TENURE
0.1 yrs

James Brooks

TITLE
Consultant
COMPENSATION
$421K
AGE
49
TENURE
2.3 yrs
Board of Directors Tenure

Average tenure and age of the OptimizeRx board of directors in years:

1.9
Average Tenure
61.5
Average Age
  • The average tenure for the OptimizeRx board of directors is less than 3 years, this suggests a new board.
Board of Directors

Gus Halas

TITLE
Chairman
COMPENSATION
$131K
AGE
67
TENURE
1.9 yrs

Will Febbo

TITLE
CEO & Director
COMPENSATION
$923K
AGE
49

Jay Pinney

TITLE
Head of Medical Advisory Board
COMPENSATION
$113K
AGE
61
TENURE
1.2 yrs

Lynn Vos

TITLE
Independent Director
COMPENSATION
$103K
AGE
62
TENURE
3.7 yrs

Jim Lang

TITLE
Independent Director
COMPENSATION
$120K
AGE
53
TENURE
2.3 yrs

Pat Spangler

TITLE
Independent Director
COMPENSATION
$106K
AGE
62
TENURE
1.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
13. May 19 Sell AWM Investment Company Inc. Company 09. May 19 13. May 19 -82,126 $13.76 $-1,120,224
19. Mar 19 Sell AWM Investment Company Inc. Company 15. Mar 19 18. Mar 19 -21,397 $15.15 $-322,108
20. Dec 18 Buy William Febbo Individual 19. Dec 18 19. Dec 18 2,000 $9.94 $19,880
20. Dec 18 Buy Miriam Paramore Individual 19. Dec 18 19. Dec 18 1,015 $9.85 $9,998
08. Nov 18 Buy William Febbo Individual 07. Nov 18 07. Nov 18 600 $16.32 $9,792
10. Aug 18 Sell Douglas Baker Individual 09. Aug 18 10. Aug 18 -4,784 $12.05 $-57,468
28. Jun 18 Buy Patrick Spangler Individual 27. Jun 18 27. Jun 18 95 $9.95 $945
27. Jun 18 Buy Ellen Vos Individual 22. Jun 18 25. Jun 18 1,800 $10.72 $18,852
26. Jun 18 Buy Miriam Paramore Individual 22. Jun 18 22. Jun 18 100 $10.50 $1,050
25. Jun 18 Buy William Febbo Individual 22. Jun 18 22. Jun 18 1,000 $10.50 $10,500
18. Jun 18 Buy Miriam Paramore Individual 15. Jun 18 15. Jun 18 5,000 $8.11 $40,346
X
Management checks
We assess OptimizeRx's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. OptimizeRx has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

OPRX News

Simply Wall St News

Do Institutions Own OptimizeRx Corporation (NASDAQ:OPRX) Shares?

The big shareholder groups in OptimizeRx Corporation (NASDAQ:OPRX) have power over the company. … Generally speaking, as a company grows, institutions will increase their ownership. … OptimizeRx is not a large company by global standards.

Simply Wall St -

Does OptimizeRx Corporation (NASDAQ:OPRX) Have A Volatile Share Price?

Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … While we should keep in mind that Warren Buffett has cautioned that 'Volatility is far from synonymous with risk', beta is still a useful factor to consider. … A stock with a beta greater than one is more sensitive to broader market movements than a stock with a beta of less than one.

Simply Wall St -

Why I Like OptimizeRx Corporation (NASDAQ:OPRX)

I've been keeping an eye on OptimizeRx Corporation (NASDAQ:OPRX) because I'm attracted to its fundamentals. … Looking at the company as a whole, as a potential stock investment, I believe OPRX has a lot to offer. … is a company with

Simply Wall St -

The OptimizeRx Share Price Is Up 399% And Shareholders Are Delighted

Given that OptimizeRx only made minimal earnings in the last twelve months, we'll focus on revenue to gauge its business development. … As a general rule, if the market is looking past earnings to focus on revenue, there is a hope for, or expectation of, strong growth. … The main reason for this is that fast revenue growth can be readily extrapolated into a profitable future, but stagnant revenue cannot.

Simply Wall St -

Is OptimizeRx Corporation's (NASDAQ:OPRX) CEO Paid Enough Relative To Peers?

In 2016 Will Febbo was appointed CEO of OptimizeRx Corporation (NASDAQ:OPRX). … First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Will Febbo's Compensation Compare With Similar Sized Companies?

Simply Wall St -

Why We’re Not Keen On OptimizeRx Corporation’s (NASDAQ:OPRX) 0.005% Return On Capital

To be precise, we'll consider its Return On Capital Employed (ROCE), as that will inform our view of the quality of the business. … Understanding Return On Capital Employed (ROCE). … ROCE measures the 'return' (pre-tax profit) a company generates from capital employed in its business.

Simply Wall St -

When Should You Buy OptimizeRx Corporation (NASDAQ:OPRX)?

saw a decent share price growth in the teens level on the NasdaqCM over the last few months. … With many analysts covering the stock, we may expect any price-sensitive announcements have already been factored into the stock’s share price? … Let’s examine OptimizeRx’s valuation and outlook in more detail to determine if there’s still a bargain opportunity

Simply Wall St -

Could OptimizeRx Corporation's (NASDAQ:OPRX) Investor Composition Influence The Stock Price?

Generally speaking, as a company grows, institutions will increase their ownership. … OptimizeRx is a smaller company with a market capitalization of US$114m, so it may still be flying under the radar of many institutional investors. … Our analysis of the ownership of the company, below, shows that.

Simply Wall St -

Read This Before Judging OptimizeRx Corporation's (NASDAQ:OPRX) ROE

This article is for those who would like to learn about Return On Equity (ROE). … The formula for return on equity is: … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

How Should Investors React To OptimizeRx Corporation's (NASDAQ:OPRX) CEO Pay?

This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … According to our data, OptimizeRx Corporation has a market capitalization of US$199m, and pays its CEO total annual compensation worth US$420k. … Most shareholders would consider it a positive that Will Febbo takes less compensation than the CEOs of most similar size companies, leaving more for shareholders.

Simply Wall St -

OPRX Company Info

Description

OptimizeRx Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers. The company’s cloud-based solutions support patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information; and network consists of electronic health records platforms, which provide the ambulatory patient market with access to their workflow at the point-of-care. Its products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems to search, print, or electronically dispense directly to patients, as well as for a network of pharmacies; and Brand and Clinical Messaging that includes various brand awareness and clinical messaging services consisting of brand awareness messages, reminder ads, clinical messages, and unbranded messages targeted by specialty, diagnostic code, and other criteria. The company’s products and applications also comprise brand support services, which focuses on educating and working with pharmaceutical manufacturers on identifying, formulating, and implementing new eRx media strategies, including drug file integration, sales force training, and strategy development services for promoting their products. It also operates Mobile Health Messenger platform that provides interactive health messaging for enhanced medication adherence, care coordination, and patient engagement; and HIPAA-compliant, an automated and mobile messaging platform that allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance. OptimizeRx Corporation is based in Rochester, Michigan.

Details
Name: OptimizeRx Corporation
OPRX
Exchange: NasdaqCM
Founded:
$188,683,731
12,095,111
Website: http://www.optimizerx.com
Address: OptimizeRx Corporation
400 Water Street,
Suite 200,
Rochester,
Michigan, 48307,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM OPRX Common Shares Nasdaq Capital Market US USD 23. Jun 2005
Number of employees
Current staff
Staff numbers
37
OptimizeRx employees.
Industry
Health Care Technology
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/16 02:05
End of day share price update: 2019/05/15 00:00
Last estimates confirmation: 2019/05/09
Last earnings filing: 2019/05/08
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.